No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
about
Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer
P2860
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
@en
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
@nl
type
label
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
@en
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
@nl
prefLabel
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
@en
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
@nl
P50
P356
P1476
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
@en
P304
1903-4; author reply 1904-5
P356
10.1200/JCO.2007.15.7776
P407
P577
2008-04-01T00:00:00Z